DMAA amends merger agreement with Power Analytics; valuation set at $2.85 billion
On September 8, 2026, Drugs Made In America Acquisition Corp. and Power Analytics Global Corp entered an Amended and Restated Definitive Merger Agreement that replaces the existing agreement in its entirety. The parties set a fixed closing valuation of $2.85 billion for Power Analytics, replacing the prior $1.0 billion target and $300 million floor. Completion depends on conditions including shareholder approval, an acquisition of APQC Inc, and a minimum cash condition, so the deal has not closed.
Key points
- Amended and Restated Definitive Merger Agreement dated September 8, 2026, replacing the Existing Agreement from April 29, 2026.
- Closing valuation of $2.85 billion, replacing the $1.0 billion target valuation and $300 million floor valuation.
- Merger Consideration capped at 265,116,279 Domesticated DMAA Common Shares, based on a Reference Price of at least $10.75.
- Closing requires shareholder approval, completion of the APQC Acquisition and Available Closing Cash of at least $15 million.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.